C-EUBCJupiter Neurosciences
micellar resveratrol, neuroinflammation, oral softgel
modulatingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-EUBC
C-EUBCC-EUBCmicellar resveratrol, neuroinflammation, oral softgel
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Jupiter Neurosciences presents itself as a clinical-stage drug platform company focused on neuroinflammation, stating that its mission is to make a significant impact for patients and society through a safe oral medication for Alzheimer’s disease and rare diseases. It says its flagship product, JOTROL, is the first and only resveratrol product that safely reaches therapeutic levels without gastrointestinal side effects, and that its anti-inflammatory and oxidative-stress-reducing mechanisms, oral micellar delivery, ability to cross the blood-brain barrier, and safety profile create potential applications across multiple diseases, with a long-term focus on Alzheimer’s disease and parallel development for orphan diseases.
SourceJupiter Neurosciences presents itself as a clinical-stage drug platform company focused on treating neuroinflammation, with the belief that its micellar resveratrol product JOTROL™ can safely achieve therapeutic levels without gastrointestinal side effects, cross the blood-brain barrier, and support treatment across multiple diseases. The company states a long-term focus on Alzheimer’s disease while also pursuing treatments for rare diseases, framing its platform as a safe, oral approach intended to benefit patients and society.
SourceThe company presented the view that neurodegenerative decline and unhealthy aging are meaningfully driven by inflammatory and metabolic dysfunction in the brain, and that these processes may be addressed with a high-bioavailability resveratrol therapy. It positioned its program around the belief that resveratrol’s biological effects are promising but have been limited by delivery, and that improving absorption and brain-relevant exposure could support treatment of disorders such as Alzheimer’s disease, especially where inflammation and ApoE4-linked risk are involved.
SourceNo company beliefs, mission statement, or theory claims are visible in the provided snapshot text; the page shown is a Wayback verification interstitial rather than preserved company content.
Source